Signatera Looks Deeper
Personalized tumor-informed test for actionable intelligence
Explore the three new studies recently presented at the 2020 American Society of Clinical Oncology (ASCO) virtual conference and access additional content below. The oral presentation and 2 posters highlight the unique applications of Signatera to detect recurrence using circulating-tumor DNA (ctDNA).
On-Demand ASCO Presentations
Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy and to identify patients at high risk of recurrence in patients with stage I-III CRC
A study evaluating the validity of Signatera ctDNA assay to detect molecular residual disease (MRD) in CRC patients who are at high risk of recurrence, during and after adjuvant chemotherapy. Serial ctDNA analysis detected MRD up to 16.6 months before radiologic imaging.
-
Tumor informed assessment of molecular residual disease and its incorporation into practice for patients with early and advanced stage colorectal cancer (CRC MRD Consortia)
ABSTRACT / POSTER: 4108 • 100
Pashtoon Kasi, MD, MSAssistant Professor, College of Medicine and Oncology, University of Iowa -
Characterization of clonal hematopoiesis of indeterminate potential (CHIP) mutations from germline whole exome sequencing Data
ABSTRACT / POSTER: 1525 • 17
Hsin Ta Wu, PhDManager, Bioinformatics (Oncology & Algorithm Development), Natera
